We are live on ! Find out more
FC

Fairpointe Capital Portfolio holdings

AUM $66.3M
1-Year Est. Return 101.32%
This Fund
S&P 500
This Quarter Est. Return
+8.72%
1 Year Est. Return
+101.32%
3 Year Est. Return
+48.06%
5 Year Est. Return
+95.29%
10 Year Est. Return
–
AUM
$6.87B
AUM Growth
+$918M
Cap. Flow
+$404M
Cap. Flow %
5.88%
Top 10 Hldgs %
30.67%
Holding
79
New
4
Increased
35
Reduced
33
Closed
3

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$186M
2
AA icon
Alcoa
AA
+$148M
3
PPO
POLYPORE INTERNATIONAL, INC
PPO
+$130M
4
CTXS
Citrix Systems Inc
CTXS
+$104M
5
FTI icon
TechnipFMC
FTI
+$87.3M

Top Sells

Rank Stock Value
1
MOLXA
MOLEX INC CL-A
MOLXA
+$93.4M
2
MOLX
MOLEX INC
MOLX
+$90.6M
3
BSX icon
Boston Scientific
BSX
+$74M
4
BLC
BELO CORP SER A
BLC
+$57.9M
5
LUV icon
Southwest Airlines
LUV
+$50.2M

Sector Composition

Rank Sector Weight
1 Technology 29.22%
2 Industrials 16.12%
3 Healthcare 10.99%
4 Communication Services 9.03%
5 Financials 7.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOLXA
76
DELISTED
MOLEX INC CL-A
MOLXA
– –
-2,439,226
Closed -$93.4M
1 2 3
4

Similar funds

EFM
Ennismore Fund Management London, United Kingdom $71.7M AUM 92.16% 1-Year Est. Return
NI
Northwood Investors Denver, Colorado $73.8M AUM
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
WSC
White Square Capital London, United Kingdom $14.7M AUM 151.72% 1-Year Est. Return
AGEC
Ark Global Emerging Companies Salt Lake City, Utah $14M AUM
CIA
CSat Investment Advisory Detroit, Michigan $119M AUM 77.51% 1-Year Est. Return
FLSMF
Fundsmith Long/Short Master Fund Grand Cayman, Cayman Islands $121M AUM
OHS
Odey Holdings (Switzerland) Zurich, Switzerland, Switzerland $11.1M AUM 64.12% 1-Year Est. Return

Fairpointe Capital's Q4 2013 Portfolio in Review

As of Q4 2013, Fairpointe Capital held 79 positions worth $6.87B, up 15% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Fairpointe Capital deployed $404M of net new capital in Q4 2013, opening 4 new positions and adding to 35 existing holdings. Its largest new stake was Alcoa: 6,662,124 shares worth $170M.

By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Boston Scientific, an estimated $74M trimmed.

  • Fairpointe Capital's largest Q4 2013 buy was Alcoa: 6,662,124 shares worth $170M.
  • Fairpointe Capital added most to Edwards Lifesciences in Q4 2013, an estimated $186M increase.
  • Fairpointe Capital's biggest Q4 2013 reduction was Boston Scientific, cutting an estimated $74M.
  • Fairpointe Capital fully exited MOLEX INC CL-A in Q4 2013, selling an estimated $93.4M.
  • Fairpointe Capital's ten largest holdings make up 31% of its $6.87B portfolio in Q4 2013.
  • Fairpointe Capital opened 4 new positions and closed 3 in Q4 2013.
  • Fairpointe Capital's portfolio value rose 15% quarter-over-quarter to $6.87B.

Based on Fairpointe Capital's 13F filing for Q4 2013, filed 11 Feb 2014.